Searched for
CHASE PHARMA
Dalal Street Week Ahead: Lower volatility signals calm, but resistance looms largeIndian markets concluded the week on a strong note, driven by consistent buying interest and a significant drop in volatility. The Nifty in...- Christy Mathai used market dip to buy insurance, logistics stocks; here's his sector-by-sector playbookFund Manager Christy Mathai sees easing war-driven inflation fears, expecting a shorter earnings hit. He's selectively adding to his portfo...
- 'Time to cherry pick again': Porinju Veliyath says small and midcaps have bottomed & Thomas Cook is his latest buyPorinju Veliyath sees the correction in small and midcap stocks ending. He believes patient investors will find rewards. Thomas Cook India ...
- SBI in $1 billion funding for Sun Pharma’s US dealState Bank of India is set to commit up to $1 billion to fund Sun Pharmaceutical Industries Ltd.'s $12 billion acquisition of Organon & Co....
- Molecule glue drugs shake up cancer care, draw big moneyHarvard-born idea doubles survival in trials, triggers pharma frenzy as cos race to target 'undruggable' proteins with next-gen glue therap...
- Up to 531% returns: 23 small & midcap multibaggers you might have missed in 2026Several small and midcap stocks have achieved multibagger status in 2026, offering substantial returns. Companies in sectors like fiber opt...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- Red alert: 15 stocks most vulnerable to FII selling as DIIs refuse to step inForeign institutional investors have divested approximately $53 billion from Indian equities since September 2024, leading to significant o...
- Earnings season is strong, but Q1 pain is coming: Dipan MehtaMarket expert Dipan Mehta finds India's current earnings season strong. He notes that future quarters will test corporate India due to pote...
- Rupee slide to 94-95 is a goldmine for these 3 sectors, says Amisha VoraThe Indian rupee's significant fall presents a major investment opportunity. Experts advise focusing on export-oriented sectors like pharma...
- Sun Pharma explores funding mix for $12 billion Organon dealGlobal lenders are exploring various financing options for Sun Pharmaceutical Industries' proposed $12 billion acquisition of Organon & Co....
- Who is Lorna Hajdini? JPMorgan executive faces shocking abuse claims by married colleagueA lawsuit against a JPMorgan executive has raised serious claims of workplace harassment and abuse. A junior Indian employee has accused a ...
- Are metals turning defensive? 5-year returns rival, even beat traditional safe havensMetal stocks are outperforming defensive sectors, delivering strong returns driven by structural demand shifts and supply constraints. Fact...
- Sensex slips 100 pts, Nifty below 24,100 as fading peace hopes and surging oil prices spook investorsIndian stock markets, Sensex and Nifty, saw a dip on Tuesday. This followed a strong performance the previous day. Investor sentiment was a...
- Buy the dip, but avoid IT, back pharma & power, says Rudramurthy BVIndian markets are experiencing a healthy correction, according to Vachana Investments' MD, CA Rudramurthy BV. He advises waiting for speci...
- ETMarkets Smart Talk | Financials, industrials, healthcare top picks for FY27: Nimesh ChandanDespite geopolitical tensions and rising oil prices, Nimesh Chandan of Bajaj Finserv AMC believes India's structural economic story remains...
- Dalal Street Week Ahead: Sector rotation signals a need for disciplined approachIndian markets showed resilience, recovering from early dips to end the week higher. Despite a rebound, a strong resistance zone looms, sug...
- Cipla jumps 2% after UK arm sells stake in Chase PharmaCipla had picked a 14.6 per cent stake in Chase Pharma for $1.5 million via a syndicated venture in 2014.
- Money chase: Pharma cos knockEver-Increasing R&D expenditure has forced domestic pharmaceutical companies to scout for alternative funding mechanism to finance their re...
Load More
